Efficacy and toxicity of Eudragit-coated chitosan–succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis

    loading  Checking for direct PDF access through Ovid


A targeted delivery system for inflammatory bowel disease (IBD), Eudragit L100 (EuL)-coated chitosan (Ch)–succinyl-prednisolone (SP) conjugate microspheres (Ch–SP-MS/EuL), were designed and examined in vivo for efficacy and toxicity. Their preparation was conducted in the same manner as previously; that is, by synthesis of the conjugate by carbodiimide coupling of Ch and SP, conversion into microspheres (Ch–SP-MS), and coating of Ch–SP-MS with EuL. Experimental colitis was induced by instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS) into the colon in rats. Drugs were administered once or twice a day intragastrically for three consecutive days. Visible colitis severity, colon/body weight ratio and myeloperoxidase activity were measured as inflammatory indices. Toxicity was examined from the decrease in the thymus/body weight ratio. Efficacy was dose-dependent and the greatest in the order Ch–SP-MS/EuL > Ch–SP-MS > prednisolone (PD) alone, and Ch–SP-MS/EuL showed excellent recovery of colitis states. Toxicity was the greatest in the order PD ≫ Ch–SP-MS > Ch–SP-MS/EuL. Ch–SP-MS and Ch–SP-MS/EuL reduced significantly the thymic atrophy caused by PD. It was demonstrated that Ch–SP-MS/EuL enhanced effectiveness of PD and reduced toxic side effects of PD greatly. Also, these results established the prediction by previous in vitro and in vivo studies.

    loading  Loading Related Articles